Full Publication Of Randomized Scandinavian Dose Escalation Trial For LS SCLC

03 Mar, 2021

Dr. Rajesh Bollam

Image

45Gy / 30 Fx / 3 weeks vs 60Gy / 40 Fx / 4 weeks
⬆️ 2a OS 74.2% vs 48.1%
⬆️ Med OS 37.2 mo vs 22.6 mo
↗️ Med PFS 18.6 mo vs 10.9 mo (p=0.13)
➡️ Grade 3+ toxicity and SAEs
First benefit of dose escalation in NSCLC / SCLC since SBRT for stage I NSCLC
Discussion
- Phase II
- Long term OS not yet available
- OS in control arm comparable to literature
- Lack of PFS & LC benefit due to difficult image interpretation ?
- FDG-PET staging & TV definition

Add a comment